Tokio Marine Asset Management Co. Ltd. Purchases 78 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Tokio Marine Asset Management Co. Ltd. increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.2% during the fourth quarter, Holdings Channel reports. The firm owned 776 shares of the medical research company’s stock after buying an additional 78 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Bio-Rad Laboratories were worth $251,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. ING Groep NV bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $44,000. GAMMA Investing LLC bought a new position in Bio-Rad Laboratories in the 4th quarter valued at about $42,000. Bfsg LLC bought a new position in Bio-Rad Laboratories in the 4th quarter valued at about $77,000. Signaturefd LLC raised its holdings in Bio-Rad Laboratories by 15.8% in the 4th quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 48 shares during the period. Finally, Banque Cantonale Vaudoise raised its holdings in Bio-Rad Laboratories by 25.0% in the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock valued at $135,000 after acquiring an additional 75 shares during the period. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $275.94 on Monday. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $473.50. The company has a market cap of $7.87 billion, a P/E ratio of -12.84 and a beta of 0.87. The business has a fifty day simple moving average of $324.94 and a 200 day simple moving average of $316.96.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The business had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. During the same period in the prior year, the company earned $3.31 EPS. Bio-Rad Laboratories’s revenue for the quarter was down 6.7% on a year-over-year basis. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. UBS Group increased their price target on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Royal Bank of Canada lowered their target price on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average price target of $468.00.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 17.06% of the stock is owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.